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Abstract: A simple synthetic route affording 27%–85% yields of benzo[6,7][1,5]diazocino[2,1-
a]isoindol-12(14H)-one ring systems from readily available 3-(2-oxo-2-phenylethyl) isobenzofuran-
1(3H)-ones and 2-(aminomethyl)aniline starting materials in toluene and catalysed by p-toluene-
sulfonic acid is developed. The 1H- and 13C-NMR spectra of the final products were assigned using 
a variety of one and two-dimensional NMR experiments. The distinction between the two potential 
isomers of the final products was made on the basis of heteronuclear multiple bond connectivity 
(HMBC) NMR spectra. 
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1. Introduction 
In recent years the synthesis and chemistry of medium ring heterocycles has attracted 
considerable attention because they are often present in biologically active natural products and 
because of their broad pharmacological profile [1]. Nitrogen-containing eight-membered 
heterocycles such as azocines and diazocines are known to exhibit a number of important biological 
properties [2–5]. The general strategies towards the synthesis of eight-membered heterocycles remain 
an active area of research and the most common synthetic approach to construct diazocine rings 
involves the conventional condensation reaction of 2-aminobenzophenones. However, this method 
is time-consuming, and the yield varies with different substrates. Furthermore, the syntheses of 2-
aminobenzophenones can be fairly complicated and expensive [6]. As a result, synthetic strategies 
for diazocines preparation are limited [7]. 
The isoindole ring system plays a key role in many pharmaceutical agents owing to their broad 
range of biological activities [8–14]. Isoindolinones are the core of many natural products and 
biologically active compounds such as the benzazepine alkaloids lennoxamine (1) and jamtine (2) 
(Figure 1). The literature shows that the occurrence of medium-sized rings with two nitrogen atoms 
in bio-active compounds increases the pharmaceutical strength and activities of the compounds. The 
[1,5]benzodiazocines are known as homologs of 1,4-benzodiazepines and inhibitors of 17β-
hydroxysteroid dehydrogenase type 3. The 17β-hydroxysteroid dehydrogenases play key roles in the 
formation of active intracellular sex steroids [15]. Impairment of this testosterone-converting enzyme 
has been shown to be responsible for male pseudohermaphroditism [16], moreover, 
[1,5]benzodiazocine derivatives showed low to moderate ability to inhibit the 17β-hydroxysteroid 
dehydrogenase type 3 enzyme which can be used in the treatment of hormone-dependent cancer. 
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Interest and research in the preparation of compounds containing eight-membered rings has 
increased considerably in recent years. However, the formation of these ring systems is a challenge 
for synthetic chemistry researchers. Due to unfavourable entropic and enthalpic effects, the ring 
closure to form eight-membered rings by intramolecular cyclisation reactions is often difficult in 
comparison to smaller sized rings. As a result, the usual synthetic strategies for the preparation of 
other ring systems cannot always be applied to eight-membered rings. Several conventional 
approaches such as intramolecular cyclization, intermolecular cyclization, palladium-catalyzed, Ugi 
Four-Center Three-Component coupling reaction (U-4C-3CR), use of microwave radiation, Morita–
Baylis–Hillman reaction and intramolecular Friedel–Crafts strategies have been reported in the 
literature [17–27]. Despite the large number of literature reports on the conventional synthesis of 
diazocine skeletons, these conventional methods suffer from some drawbacks such as long reaction 
times, harsh reaction conditions, low-product yields, high cost, toxic by-products and use of toxic 
catalysts. Therefore, there is a need to introduce new and more efficient methods in order to develop 
the synthesis of medium-sized rings in the pharmaceutical industry. Interesting biological activities 
are shown by compounds containing five or six membered heterocyclic rings fused to diazocines [28–
34]. Compound 3, a potent and orally bioavailable Smac mimetic, inhibits cell growth and induces 
apoptosis in cancer cells and has been shown to be a potent antagonist of inhibitor of apoptosis 
proteins (IAPs). It is in phase 1 clinical trials for the treatment of human cancer [35–37]. 
 
Figure 1. Biologically active isoindoles and fused diazocines 1–3. 
2. Results and Discussion 
Our interest in the synthesis of heterocyclic rings fused to medium sized rings led us to envisage 
a straightforward synthetic approach to the benzo[6,7][1,5]diazocine[2,1-a]isoindol-12-(14H)-one ring 
system [38,39]. A number of 3-(2-oxo-2-phenylethyl) isobenzofuran-1(3H)-ones 4a–m were 
synthesized following the reported literature procedures [40–51] (Table 1).  
Table 1. Formation of isobenzofuran-1(3H)-ones 4a–4m. 
Compound R Yield (%) 
Melting Points (°C) 
Found Literature [Reference] 
4a C6H5 74 142–44 146–147 [42] 
4b 4-ClC6H4 65 139–41 146 [48] 
4c 3-ClC6H4 76 136–37 142–144 [51] 
4d 2-ClC6H4 79 95–96 91–92 [47] 
4e 4-BrC6H4 45 144–45 147–149 [42] 
4f 3-BrC6H4 75 127–29 124–127 [52] 
4g 2-BrC6H4 67 107–108 — 
4h 4-FC6H4 81 135–36 130–133 [52] 
4i 2-FC6H4 62 116–117 114 [47] 
4j 3-CH3-C6H4 56 108–109 104–105 [47] 
4k 2-CH3C6H4 63 102–103 — 
4l 3-CH3OC6H4 68 110–111 134–135 [42] 
4m 2-Thienyl 54 135–137 138 [49] 
All isobenzofuran-1(3H)-ones synthesized in this work, except compounds 4g and 4k, are known 
and their melting points and spectral characterization showed good agreement with the literature 
values. Compounds 4g and 4k were fully characterized by spectral data. Previous work had reported 
the reaction of hydrazine with a number of 3-(2-oxo-2-phenylethyl) isobenzofuran-1(3H)-ones to 
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yield pyrazolo[5,1-a]isoindol-8-ones [52]. More recently the reaction of o-phenylenediamine with 3-
(2-oxo-2-phenylethyl) isobenzofuran-1(3H)-ones has been reported to yield 7,7a-dihydro-12H-
isoindolo[2,1-a][1,5]benzodiazepin-12-one derivatives [53]. We anticipated that the reaction of 3-(2-
oxo-2-phenylethyl) isobenzofuran-1(3H)-ones 4 with 2-aminobenzylamine could yield either 
compound 5 or 6 (Scheme 1). 
 
Scheme 1. Synthesis of benzo[6,7][1,5]diazocine[2,1-a]isoindol-12(14H)-one 5a–5m. Reagents and 
conditions: (a) RCOCH3, NaOH, RT. (b) 2-aminobenzylamine, p-TsOH, toluene, reflux 24 h. 
Benzo[6,7][1,5]diazocine[2,1-a]isoindol-12(14H)-one 5a–5m were prepared in a simple two-step 
sequence. In the first step 3-(2-oxo-2-phenylethyl) isobenzofuran-1(3H)-ones 4a–4m were prepared 
in moderate to good yields following a known reported literature method [47]. Reaction of 4a–4m 
with 2-aminobenzylamine afforded 5a–5m in moderate to good yields (27%–85%) (Table 2). We 
envisaged that either regioisomer 5 or 6 could form, depending upon the mechanistic pathway 
followed. 
Table 2. Formation of benzo[6,7][1,5]diazocine[2,1-a]isoindol-12(14H)-ones 5a–5m. 
R Compound Yield (%)
C6H5 5a 74 
4-ClC6H4 5b 75 
3-ClC6H4 5c 73 
2-ClC6H4 5d 73 
4-BrC6H4 5e 85 
3-BrC6H4 5f 72 
2-BrC6H4 5g 27 
4-FC6H4 5h 72 
3-FC6H4 5i 55 
3-CH3C6H4 5j 68 
2-CH3C6H4 5k 40 
3-CH3OC6H4 5l 62 
2-Thienyl 5m 32 
To investigate the regiochemistry of the reaction (Scheme 1), a full characterisation by NMR 
spectroscopy and assignment of compounds 5a, 5b, 5f and 5h were undertaken (Tables 3 and 4). The 
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numbering scheme is presented in Figure 2 and assignments of the proton and carbon spectra are 
summarized in Tables 3 and 4, respectively. 
 
Figure 2. Numbering scheme of 5a for the purpose of NMR assignments. 
Table 3. Proton NMR assignments of compounds 5a, 5b, 5f and 5h (chemical shift, ppm). [a] 
Proton [b] Compound 5a Compound 5b Compound 5f Compound 5h 
7<‘> 2.30 2.30 2.30 2.31 
7<‘‘> 3.66 3.59 3.58 3.60 
14<‘> 3.71 3.66 3.67 3.68 
7a 4.55 4.52 4.53 4.53 
14<‘‘> 5.31 5.31 5.32 5.31 
4 7.03 7.02 7.02 7.02 
2 7.13 7.14 7.15 7.14 
3 7.30 7.30 7.31 7.23–7.33 
10 7.47 7.49 7.43–7.51 7.48 
9 7.52–7.65 7.53–7.63 7.55–7.63 7.55–7.62 
8 7.52–7.65 7.53–7.63 7.55–7.63 7.55–7.62 
4’ 7.52–7.65 — 7.72 — 
3’ 7.52–7.65 7.53–7.63 — 7.23–7.33 
5’ 7.52–7.65 7.53–7.63 7.43–7.51 7.23–7.33 
1 7.76 7.76 7.76 7.76 
11 7.83 7.83 7.83 7.83 
2’ 8.18 8.13 8.36 8.19 
6’ 8.18 8.13 8.07 8.19 
[a] All chemical shifts quoted were referenced to the residual solvent signal of CDCl3; [b] <‘> and <‘‘> 
represent germinal protons with different chemical shifts.  
Table 4. Carbon NMR assignments of compounds 5a, 5b, 5f and 5h (chemical shifts, ppm). [a] 
Carbon Compound 5a Compound 5b Compound 5f Compound 5h 
7 36.28 36.19 36.30 36.24  
14 42.02 42.00 41.99 42.01  
7a 56.11 56.30 56.22 56.33  
4 121.21 121.14 121.11 121.19  
8 121.91 121.84 121.89 121.84  
11 123.99 124.07 124.06 124.06  
2 125.09 125.28 125.40 125.19  
14a 126.16 126.08 125.95 126.14  
2’ 127.74 129.04 131.02 129.92 3JC-F 8.7 Hz 
6’ 127.80 129.08 126.09 129.86 3JC-F 8.7 Hz 
3 128.80 128.84 128.87 128.83  
10 128.84 128.94 128.96 128.92  
3’ 129.00 129.40 123.57 116.09 2JC-F 21.7 Hz 
5’ 129.13 129.34 130.54 116.23 2JC-F 21.7 Hz 
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4’ 131.42 137.76 134.29 164.80 1JC-F 252.9 Hz 
1 131.64 131.68 131.69 131.66  
9 131.78 131.85 131.88 131.82  
11a 132.62 132.59 132.57 132.60  
1’ 137.18 135.58 139.20 133.38  
7b 143.90 143.69 143.66 143.75  
4a 148.78 148.50 148.35 148.58  
6 165.68 164.43 164.23 164.35  
12 167.16 167.12 167.12 167.13  
[a] All chemical shifts quoted were referenced to the carbon signal of CDCl3. 
The assignments were based on a combination of proton and carbon homo- and heteronuclear 
2D NMR experiments. There is potential to form two isomers (compounds 5 and 6, Scheme 1) in the 
final step of the reaction and the chemical shift assignments were made to establish the structure of 
the products formed. Many of the long range proton-carbon correlations observed in the 
heteronuclear multiple bond connectivity spectra (HMBC: see supplementary material) fit either of 
the two isomers (Figure 3).  
 
Figure 3. Potential reaction products formed. 
However, correlations from the methylene group protons H14 to the carbonyl group C12 are 
indicative of structure 5. The assignment of C12 is confirmed by the long range proton-carbon 
correlation between H11 and C12. 
Protons H7 and H14 from the methylene groups correlate with carbon 7a. Typically, correlations 
spanning two to three bonds are observed in the HMBC experiment and the methylene group protons 
next to the nitrogen in structure 6 are too far removed from carbon atoms C7a and C12 and, therefore, 
highly unlikely to be observed if structure 6 were formed in the reaction. The NMR analyses fully 
support the conclusion that isomer 5 was formed in this reaction. Other derivatives, where no 2D-
NMR data were acquired follow the proton and carbon chemical shifts patterns of the fully 
characterized derivatives 5a, 5b, 5f and 5h and, therefore, the same regiochemistry was inferred. 
3. Materials and Methods 
3.1. General Information 
All chemicals were purchased form Sigma Aldrich (Dorset, UK) or Merck (Nottingham, UK)  
and were used without further purification. Melting points were determined using a Gallenkamp 
melting point apparatus (Thermo Fisher Scientific, Paisley, UK) and are uncorrected. NMR spectra 
(at 600 MHz for protons and 151 MHz for 13C) were recorded on a ECA 600 MHz NMR instrument 
(JEOL Co Ltd., Tokyo, Japan) equipped with a 5 mm gradient broadband probe. Tetramethylsilane 
was used as internal standard and solvents as indicated. Chemical shifts were measured in ppm (δ) 
relative to TMS (0.00 ppm) or the residual solvent peaks. Coupling constants (J) are reported in Hertz 
(Hz). LC-MS spectra were obtained with a spectrometer equipped with an ESI source (Varian: 210 
LC pumps × 2, 1200 L Quadrapole MS/MS, 410 autosampler) (Varian (now Agilent), Oxford, UK) 
using a gradient solvent system of A: Water/0.1% formic acid and B: acetonitrile/0.1% formic acid. 
Infrared spectra were recorded with a Varian 800 FT-IR spectrophotometer (Varian). 
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3.2. General Procedure for the Synthesis of 3-(2-Oxo-2-phenylethyl)isobenzofuran-1(3H)-ones 4a–4m 
To a stirred solution of 2-carboxybenzaldehyde (15.0 g; 0.1 mol) dissolved in ethanol (50 mL) in 
a 1 L three-necked round bottom flask was added the relevant acetophenone (0.1 mol). The flask was 
immersed in a bath of crushed ice. Sodium hydroxide (75 mL, 1.75 M) was added dropwise and the 
mixture was stirred mechanically for 4 h. The resulting mixture was neutralized with dilute 
hydrochloric acid. Diethyl ether (approximately 50 mL) was added to precipitate the product. The 
crude product was filtered, washed with a small volume of distilled water and recrystallized from 
dichloromethane and ethanol. 
3-(2-Oxo-2-phenylethyl)isobenzofuran-1(3H)-one (4a). White powder, yield 74%, m.p. 142–144 °C (lit. 
146–147 °C [42]). IR (KBr) cm−1 1685 (C=O), 1742 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.91 (d, J = 7.6 Hz, 
1H), 7.68 (t, J = 7.6 Hz, 1H), 7.49–7.62 (m, 4H), 7.44 (d, J = 1.4 Hz, 1H), 7.29–7.40 (m, 1H), 6.10 (t, J = 6.5 
Hz, 1H), 3.64 (dd, J = 17.2, 6.9 Hz, 1H), 3.46 (dd, J = 17.9, 6.2 Hz, 1H). 13C-NMR (CDCl3) δ 195.74 (C=O), 
169.87 (C=O), 149.47, 135.91, 134.04, 133.60, 129.17, 128.56, 127.91, 125.61, 125.42, 122.53, 76.80, 43.38. 
MS (ESI, m/z) 251.05 [M]+. 
3-(2-(4-Chlorophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4b). White powder, yield 65%, m.p. 139–141 
°C (lit. 146 °C [48]). IR (KBr) cm−1 1691 (C=O), 1742 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.82–8.01 (m, 
3H), 7.66 (t, J = 7.3 Hz, 1H), 7.54 (t, J = 6.9 Hz, 2H), 7.45 (d, J = 8.3 Hz, 2H), 6.15 (t, J = 6.9 Hz, 1H), 3.72 
(dd, J = 17.4, 5.5 Hz, 1H), 3.36 (dd, J = 17.4, 6.4 Hz, 1H). 13C-NMR (CDCl3) δ 194.80 (C=O), 169.99 (C=O), 
149.52, 140.46, 134.48, 134.31, 129.57, 129.53, 129.19, 125.89, 125.82, 122.70, 76.79, 43.66. MS (ESI m/z) 
285.0 [M]+. 
3-(2-(3-Chlorophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4c). White powder, yield 76%, m.p. 126–127 
°C (lit. 142–144 °C [51]). IR (KBr) cm−1 1691 (C=O), 1747 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.84–7.97 
(m, 1H), 7.59–7.75 (m, 4H), 7.51–7.59 (m, 2H), 7.46 (td, J = 8.0, 5.0 Hz, 1H), 7.27–7.35 (m, 1H), 6.15 (t, J 
= 6.4 Hz, 1H), 3.73 (dd, J = 17.4, 6.0 Hz, 1H), 3.33–3.45 (m, 1H). 13C-NMR (CDCl3) δ 194.76 (C=O), 169.95 
(C=O), 149.44, 137.63, 135.25, 134.31, 133.78, 130.18, 129.54, 128.23, 126.25, 125.83, 122.66, 76.79, 43.79. 
MS (ESI m/z) 285.0 [M]+. 
3-(2-(2-Chlorophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4d). White powder, yield 79%, m.p. 95–96 °C 
(lit. 91–92 °C [47]). IR (KBr) cm−1 1678 (C=O), 1735 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.85–7.95 (m, 
1H), 7.62–7.74 (m, 1H), 7.48–7.62 (m, 3H), 7.38–7.48 (m, 2H), 7.29–7.38 (m, 1H), 6.07–6.17 (m, 1H), 3.59–
3.77 (m, 1H), 3.44–3.58 (m, 1H). 13C-NMR (CDCl3) δ 198.52 (C=O), 169.95 (C=O), 149.27, 137.93, 134.30, 
132.65, 131.31, 30.77, 129.64, 129.49, 127.21, 125.90, 125.82, 122.45, 76.79, 47.74. MS (ESI m/z) 286.9 [M]+. 
3-(2-(4-Bromophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4e). White powder, yield 45%, m.p. 144–146 
°C (lit. 147–149 °C [42]). IR (KBr) cm−1 1679 (C=O), 1740 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.86–7.98 
(m, 1H), 7.74–7.86 (m, 2H), 7.58–7.73 (m, 3H), 7.47–7.58 (m, 2H), 6.14 (t, J = 6.5 Hz, 1H), 3.71 (ddd, J = 
17.7, 6.0, 1.4 Hz, 1H), 3.35 (ddd, J = 17.5, 7.0, 1.4 Hz, 1H). 13C-NMR (CDCl3) δ 195.00 (C=O), 169.98 
(C=O), 149.51, 134.88, 134.31, 132.19, 129.64, 129.53, 129.22, 125.89, 125.83, 122.69, 76.79, 43.63. MS (ESI 
m/z) 331.1 [M]+. 
3-(2-(3-Bromophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4f). White crystals, yield 75%, m.p. 127–129 
°C (lit. 124–127 °C [52]). IR (KBr) cm−1 1688 (C=O), 1729 (C=O). 1H-NMR (CDCl3): δ (ppm) 8.08 (t, J = 
1.8 Hz, 1H), 7.89–7.96 (m, 1H), 7.79–7.89 (m, 1H), 7.69–7.79 (m, 1H), 7.60–7.69 (m, 1H), 7.48–7.60 (m, 
2H), 7.30–7.45 (m, 1H), 6.15 (t, J = 6.4 Hz, 1H), 3.68–3.80 (m, 1H), 3.37 (dd, J = 17.7, 7.1 Hz, 1H). 13C-
NMR (CDCl3) δ 194.68 (C=O), 169.95 (C=O), 149.45, 137.82, 136.71, 134.32, 131.20, 130.42, 129.55, 
126.70, 125.89, 125.84, 123.23, 122.67, 76.79, 43.77. MS (ESI m/z) 332.8 [M]+. 
3-(2-(2-Bromophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4g). White powder, yield 67%, m.p. 107–108 
°C. IR (KBr) cm−1 1684 (C=O), 1749 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.78–7.97 (m, 1H), 7.63–7.78 (m, 
1H), 7.49–7.63 (m, 3H), 7.42–7.49 (m, 1H), 7.34–7.42 (m, 1H), 7.31 (td, J = 7.8, 1.8 Hz, 1H), 6.03–6.17 (m, 
1H), 3.61 (dd, J = 17.7, 6.6 Hz, 1H), 3.41–3.54 (m, 1H). 13C-NMR (CDCl3) δ 199.38 (C=O), 169.88 (C=O), 
149.14, 140.13, 134.27, 133.90, 132.37, 129.47, 129.11, 127.65, 125.81, 125.73, 122.47, 118.87, 76.78, 47.25. 
MS (ESI m/z) 329.0 [M]+. Anal. Calcd. For: C16H11BrO3: C, 58.03; H, 3.35%. Found: C, 57.85; H, 3.59%. 
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3-(2-(4-Fluorophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4h). White powder, yield 81%, m.p. 135–136 
°C (lit. 130–133 °C [52]). IR (KBr) cm−1 1680 (C=O), 1745 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.94–8.06 
(m, 2H), 7.91 (dd, J = 7.6, 1.1 Hz, 1H), 7.60–7.72 (m, 1H), 7.50–7.60 (m, 2H), 7.12–7.23 (m, 2H), 6.15 (t, J 
= 6.5 Hz, 1H), 3.73 (dd, J = 17.5, 5.8 Hz, 1H), 3.36 (dd, J = 17.7, 7.1 Hz, 1H). 13C-NMR (CDCl3) δ 194.40 
(C=O), 170.03 (C=O), 167.01, 149.59, 134.30, 132.65, 130.93, 130.86, 129.50, 125.89, 125.80, 122.74, 116.10, 
115.95, 76.79, 43.60. MS (ESI m/z) 268.3 [M]+. 
3-(2-(3-Fluorophenyl)-2-oxoethyl)isobenzofuran-1(3H)-one (4i). White powder, yield 62%, m.p. 116–117 
°C (lit. 114 °C [47]). IR (KBr) cm−1 1684 (C=O), 1744 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.86–8.02 (m, 
2H), 7.61–7.74 (m, 1H), 7.49–7.61 (m, 3H), 7.20–7.34 (m, 1H), 7.10–7.20 (m, 1H), 6.12–6.22 (m, 1H), 3.66–
3.81 (m, 1H), 3.45 (dd, J = 6.4, 3.2 Hz, 1H). 13C-NMR (CDCl3) δ 193.92 (C=O), 170.11 (C=O), 163.04, 
161.34, 149.62, 135.50, 134.23, 130.68, 129.40, 126.00, 125.78, 124.74, 122.60, 116.20, 76.79, 48.44. MS (ESI 
m/z) 268.8 [M]+. 
3-(2-Oxo-2-(m-tolyl)ethyl)isobenzofuran-1(3H)-one (4j). White powder, yield 56%, m.p. 108–109 °C (lit. 
104–105 °C [47]). IR (KBr) cm−1 1676 (C=O), 1768 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.85–7.96 (m, 1H), 
7.69–7.82 (m, 2H), 7.60–7.69 (m, 1H), 7.47–7.60 (m, 2H), 7.31–7.47 (m, 2H), 6.17 (dd, J = 7.6, 5.7 Hz, 1H), 
3.76 (dd, J = 17.7, 5.7 Hz, 1H), 3.32–3.44 (m, 1H), 2.40 (s, 3H). 13C-NMR (CDCl3) δ 196.23 (C=O), 
170.13(C=O), 149.81, 138.71, 136.22, 134.63, 134.24, 129.40, 128.69, 128.66, 125.74, 125.39, 122.83, 76.79, 
43.76, 21.32. MS (ESI m/z): 265.1 [M]+. 
3-(2-Oxo-2-(o-tolyl)ethyl)isobenzofuran-1(3H)-one (4k). White powder, yield 63%, m.p. 102–103 °C. IR 
(KBr) cm−1 1688 (C=O), 1740 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.88–7.99 (m, 1H), 7.75–7.88 (m, 2H), 
7.60–7.74 (m, 1H), 7.48–7.60 (m, 2H), 7.21–7.33 (m, 2H), 6.10–6.22 (m, 1H), 3.75 (dd, J = 17.5, 5.6 Hz, 
1H), 3.35 (dd, J = 17.5, 7.5 Hz, 1H), 2.41 (s, 3H). 13C-NMR (CDCl3) δ 199.24 (C=O), 170.10 (C=O), 149.71, 
139.00, 136.45, 134.24, 132.33, 132.21, 129.41, 128.97, 125.96, 125.91, 125.80, 122.58, 76.79, 46.15, 21.63. 
MS (ESI m/z) 264.6 [M]+. Anal. Calcd. For: C17H14O3: C, 76.68; H, 5.30%. Found: C, 76.53; H, 5.22%. 
3-(2-(3-Methoxyphenyl)-2-oxethyl)isobenzofuran-1(3H)-one (4l). White powder, yield 68%, m.p. 110–111 
°C (lit. 134–135 °C [42]). IR (KBr) cm−1 1676 (C=O), 1768 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.91 (dd, J 
= 7.7, 1.0 Hz, 1H), 7.60–7.80 (m, 1H), 7.48–7.60 (m, 4H), 7.30–7.44 (m, 1H), 7.13 (dd, J = 8.3, 2.5, Hz, 
1H), 6.14–6.22 (m, 1H), 3.85–4.02 (m, 3H), 3.73–3.79 (m, 1H), 3.35–3.44 (m, 1H). 13C-NMR (CDCl3) δ 
196.23 (C=O), 170.13(C=O), 149.81, 138.71, 136.22, 134.63, 134.24, 129.40, 128.69, 128.66, 125.74, 125.39, 
122.83, 76.79, 43.76, 21.32. MS (ESI m/z) 265.1 [M]+. 
3-(2-Oxo-2-(thiophen-2-yl)ethyl)isobenzofuran-1(3H)-one (4m). White powder, yield 54%, m.p. 125–127 
°C (lit. 125–127 °C) [49]. IR (KBr) cm−1 1645 (C=O), 1767 (C=O). 1H-NMR (CDCl3): δ (ppm) 7.90 (d, J = 
7.6 Hz, 1H), 7.73–7.84 (m, 1H), 7.58–7.73 (m, 2H), 7.48–7.58 (m, 1H), 7.32–7.48 (m, 1H), 7.19–7.32 (m, 
1H), 7.02–7.19 (m, 1H), 6.11 (t, J = 6.5 Hz, 1H), 3.60–3.79 (m, 1H), 3.38–3.57 (m, 1H). 13C-NMR (CDCl3) 
δ 188.73 (C=O), 170.18 (C=O), 149.50, 143.44, 134.99, 134.46, 133.07, 129.61, 128.57, 125.84, 122.80, 44.18. 
MS (ESI m/z) 256.8 [M]+. 
3.3. General Procedure for the Synthesis of Benzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-ones 5a–5m 
3-(2-Oxo-2-phenylethyl)isobenzofuran-1(3H)-ones 4a–4m (4.0 × 10−3 mol) were added to 2-
aminobenzylamine (8.0 × 10−3 mol) dissolved in toluene (40 mL). To the mixture was added p-
toluenesulfonic acid monohydrate (70 mg; 3.5 × 10−4 mol) as a catalyst. The mixture was refluxed with 
stirring for 24 h and the reaction monitored using TLC. The solution was left to cool to room 
temperature and the excess solvent was removed on a rotary evaporator. The resulting solid was 
filtered, dried and recrystallized from ethanol. 
(E)-6-Phenyl-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5a). Light yellow crystals, 
yield 74%, m.p. 203–204 °C. IR (KBr) cm−1 1700 (C=O), 1623 (C=N). 1H-NMR (CDCl3): δ (ppm) 8.12–
8.21 (m, 2H), 7.83 (d, J = 7.2 Hz, 1H), 7.76 (dd, J = 7.7, 1.5 Hz, 1H), 7.51–7.64 (m, 4H), 7.37–7.51 (m, 2H), 
7.22–7.33 (m, 1H), 7.07–7.16 (m, 1H), 7.01 (dd, J = 7.7, 1.2 Hz, 1H), 5.25–5.34 (m, 1H), 4.53 (d, J = 10.7 
Hz, 1H), 3.60–3.74 (m, 2H), 2.25–2.35 (m, 1H). 13C-NMR (CDCl3) δ 167.16, 165.68, 148.78, 143.90, 137.18, 
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132.62, 131.78, 131.64, 131.42, 129.13, 129.00, 128.84, 128.80, 127.80, 127.74, 126.16, 125.09, 123.99, 
121.91, 121.14, 56.11, 42.02, 36.28. MS (ESI m/z) 339.3 [M]+. Anal. Calcd. For: C23H18N2O: C, 81.63; H, 
5.36; N, 8.28%. Found: C, 81.55; H, 5.66; N, 8.21%. 
(E)-6-(4-Chlorophenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5b). Light yellow 
crystals, yield 75%, m.p. 198–199 °C. IR (KBr) cm−1 1695 (C=O), 1653 (C=N). 1H-NMR (CDCl3): δ (ppm) 
8.10 (d, J = 8.3 Hz, 2H), 7.78–7.88 (m, 1H), 7.65–7.78 (m, 1H), 7.50–7.64 (m, 4H), 7.46 (ddd, J = 7.8, 6.0, 
2.3 Hz, 1H), 7.22–7.34 (m, 1H), 7.07–7.17 (m, 1H), 6.96–7.05 (m, 1H), 5.29 (d, J = 14.7 Hz, 1H), 4.50 (d, 
J = 10.5 Hz, 1H), 3.64 (d, J = 14.2 Hz, 1H), 3.57 (d, J = 13.3 Hz, 1H), 2.28 (dd, J = 13.8, 11.0 Hz, 1H). 13C-
NMR (CDCl3) δ 167.13, 164.43, 148.50, 143.69, 137.76, 135.58, 132.59, 131.85, 131.68, 129.40, 129.34, 
129.08, 129.04, 128.94, 128.84, 126.08, 125.28, 124.07, 121.84, 121.14, 56.30, 42.00, 36.19. MS (ESI m/z) 
373.2 [M]+. Anal. Calcd. For: C23H17ClN2O: C, 74.09; H, 4.60; N, 7.51%. Found: C, 73.85; H, 4.50; N, 
7.45%. 
(E)-6-(3-Chlorophenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5c). Light yellow 
crystals, 73%, m.p. 107–108 °C. IR (KBr) cm−1 1699 (C=O), 1653 (C=N). 1H-NMR (CDCl3): δ (ppm) 8.18 
(t, J = 2.1 Hz, 1H), 8.00 (dt, J = 7.8, 1.4 Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.74 (dd, J = 7.7, 1.5 Hz, 1H), 
7.43–7.62 (m, 5H), 7.22–7.35 (m, 1H), 7.13 (td, J = 7.6, 1.4 Hz, 1H), 7.00 (dd, J = 7.9, 1.4 Hz, 1H), 5.30 (d, 
J = 14.4 Hz, 1H), 4.51 (d, J = 10.7 Hz, 1H), 3.65 (d, J = 14.4 Hz, 1H), 3.57 (dd, J = 13.7, 1.4 Hz, 1H), 2.28 
(dd, J = 13.6, 10.8 Hz, 1H). 13C-NMR (CDCl3) δ 167.03, 164.24, 148.26, 143.57, 138.90, 135.35, 132.47, 
131.77, 131.59, 131.27, 130.20, 128.85, 128.77, 127.95, 125.93, 125.56, 125.29, 123.97, 121.80, 121.00, 56.13, 
41.89, 36.23. MS (ESI m/z) 373.2 [M]+. Anal. Calcd. For: C23H17ClN2O: C, 74.09; H, 4.60; N, 7.51%. 
Found: C, 74.20; H, 4.55; N, 7.50%. 
(E)-6-(2-Chlorophenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5d). Light brown 
crystals, yield 73%, m.p. 191–192 °C. IR (KBr) cm−1 1685 (C=O), 1552 (C=N). 1H-NMR (CDCl3,): δ (ppm) 
7.74–7.87 (m, 1H), 7.31–7.50 (m, 5H), 7.18–7.31 (m, 2H), 6.99–7.18 (m, 2H), 6.56–6.74 (m, 2H), 4.98–5.15 
(m, 2H), 4.37 (d, J = 15.1 Hz, 1H), 3.75 (dd, J = 17.5, 3.8 Hz, 1H), 3.23 (dd, J = 17.4, 8.1 Hz, 1H). 13C-NMR 
(CDCl3) δ 168.49, 167.14, 147.49, 143.58, 139.17, 132.35, 131.77, 131.60, 131.53, 130.83, 130.71, 130.19, 
128.77, 128.65, 127.34, 126.00, 125.50, 123.76, 122.03, 121.20, 55.05, 41.81, 40.23. MS (ESI m/z) 373.2 [M]+. 
Anal. Calcd. For: C23H17ClN2O: C, 74.09; H, 4.60; N, 7.51%. Found: C, 74.00; H, 4.55; N, 7.50%. 
(E)-6-(4-Bromophenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5e). Light yellow 
crystals, yield 85%, m.p. 196–197 °C. IR (KBr) cm−1 1691 (C=O), 1662 (C=N). 1H-NMR (CDCl3): δ (ppm) 
7.68–7.88 (m, 2H), 7.51–7.68 (m, 2H), 7.33–7.51 (m, 4H), 7.20–7.33 (m, 2H), 7.14 (td, J = 7.6, 1.4 Hz, 1H), 
7.03 (dd, J = 7.9, 1.4 Hz, 1H), 5.38 (d, J = 14.8 Hz, 1H), 4.46 (d, J = 10.7 Hz, 1H), 4.02 (d, J = 14.4 Hz, 1H), 
3.51 (dd, J = 13.2, 1.5 Hz, 1H), 2.35 (dd, J = 13.2, 11.2 Hz, 1H). 13C-NMR (CDCl3) δ 167.05, 164.48, 148.39, 
143.58, 135.93, 134.33, 132.47, 132.23, 132.04, 131.76, 131.58, 129.46, 129.14, 128.85, 128.76, 127.49, 
125.20, 121.75, 121.56, 121.01, 56.19, 41.90, 36.05. MS (ESI m/z) 417.1[M]+. Anal. Calcd. For: 
C23H17BrN2O: C, 66.20; H, 4.11; N, 6.71%. Found: C, 66.22; H, 4.11; N, 6.70%. 
(E)-6-(3-Bromophenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5f). White 
crystals, yield 72%, m.p. 219–220 °C. IR (KBr) cm−1 1698 (C=O), 1625 (C=N). 1H-NMR (CDCl3): δ (ppm) 
8.34 (t, J = 1.8 Hz, 1H), 8.01–8.10 (m, 1H), 7.81 (d, J = 7.3 Hz, 1H), 7.66–7.78 (m, 2H), 7.52–7.65 (m, 2H), 
7.37–7.52 (m, 2H), 7.22–7.35 (m, 1H), 7.10–7.18 (m, 1H), 6.98–7.09 (m, 1H), 5.29 (d, J = 14.7 Hz, 1H), 
4.51 (d, J = 10.5 Hz, 1H), 3.65 (d, J = 14.7 Hz, 1H), 3.56 (d, J = 13.8 Hz, 1H), 2.28 (dd, J = 13.8, 11.0 Hz, 
1H). 13C-NMR (CDCl3) δ 167.12, 164.23, 148.35, 143.66, 139.20, 134.29, 132.57, 131.88, 131.69, 131.02, 
130.54, 128.96, 128.87, 126.09, 125.95, 125.40, 124.06, 123.57, 121.89, 121.11, 56.22, 41.99, 36.30. MS (ESI 
m/z) 417.1 [M]+. Anal. Calcd. For: C23H17BrN2O: C, 66.20; H, 4.11; N, 6.71%. Found: C, 66.15; H, 4.10; 
N, 6.65%. 
(E)-6-(2-Bromophenyl)-7,7a-dihydrobenz[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5g). Colourless 
needles, yield 27%, m.p. 137–138 °C. IR (KBr) cm−1 1683 (C=O), 1653 (C=N). 1H-NMR (CDCl3): δ (ppm) 
7.78–7.85 (m, 1H), 7.53–7.63 (m, 1H), 7.36–7.52 (m, 3H), 7.20–7.34 (m, 2H), 7.06–7.20 (m, 3H), 6.59–6.70 
(m, 2H), 5.00–5.12 (m, 2H), 4.38 (d, J = 15.5 Hz, 1H), 3.74 (dd, J = 17.7, 3.6 Hz, 1H), 3.22 (dd, J = 17.5, 
7.9 Hz, 1H). 13C-NMR (CDCl3) δ 168.75, 145.90, 145.47, 140.60, 133.83, 132.12, 131.92, 131.31 130.95, 
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129.54, 128.71, 128.50, 127.52, 123.79, 122.92, 119.63, 117.21, 115.75, 55.88, 44.71, 42.10. MS (ESI m/z) 
419.1 [M]+. Anal. Calcd. For: C23H17BrN2O: C, 66.20; H, 4.11; N, 6.71%. Found: C, 66.15; H, 4.05; N, 
6.58%. 
(E)-6-(4-Fluorophenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5h). Colourless 
needles, yield 72%, m.p. 136–137 °C. IR (KBr) cm−1 1696 (C=O), 1662 (C=N). 1H-NMR (CDCl3): δ (ppm) 
8.17 (dd, J = 8.9, 5.3 Hz, 2H), 7.81 (d, J = 7.8 Hz, 1H), 7.66–7.78 (m, 1H), 7.52–7.66 (m, 2H), 7.37–7.52 
(m, 1H), 7.22–7.37 (m, 3H), 7.05–7.17 (m, 1H), 6.97–7.05 (m, 1H), 5.29 (d, J = 14.2 Hz, 1H), 4.51 (d, J = 
10.5 Hz, 1H), 3.66 (d, J = 14.2 Hz, 1H), 3.58 (d, J = 13.8 Hz, 1H), 2.29 (dd, J = 13.5, 10.8 Hz, 1H). 13C-
NMR (CDCl3) δ 167.13, 164.80, 164.35, 148.58, 143.75, 133.38, 132.60, 131.782, 131.66, 129.92, 129.86, 
128.92, 128.83, 126.14, 125.19, 124.06, 121.84, 121.19, 116.23, 116.09, 56.33, 42.01, 36.24. MS (ESI m/z) 
557.3 [M]+. Anal. Calcd. For: C23H17FN2O: C, 77.51; H, 4.81; N, 7.86%. Found: C, 77.34; H, 4.85; N, 
7.76%. 
(E)-6-(3-Fluorophenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5i). Colourless 
crystals, yield 55%, m.p. 187–189 °C. IR (KBr) cm−1 1701 (C=O), 1620 (C=N). 1H-NMR (CDCl3): δ (ppm) 
8.12–8.20 (m, 2H), 7.81 (d, J = 7.2 Hz, 1H), 7.66–7.78 (m, 1H), 7.51–7.63 (m, 4H), 7.41–7.51 (m, 1H), 7.23–
7.33 (m, 1H), 7.07–7.16 (m, 1H), 6.97–7.05 (m, 1H), 5.29 (d, J = 14.4 Hz, 1H), 4.53 (d, J = 11.0 Hz, 1H), 
3.60–3.74 (m, 2H), 2.28 (dd, J = 13.6, 10.8 Hz, 1H). 13C-NMR (CDCl3) δ 168.78, 163.25, 167.15, 162.80, 
147.68, 146.09, 145.87, 143.98, 131.87, 135.21, 131.69, 131.36, 130.90, 129.41, 128.35, 123.74, 122.91, 
117.38, 115.69, 55.59, 45.80, 41.91. MS (ESI m/z) 357.3 [M]+. Anal. Calcd. For: C23H17FN2O: C, 77.51; H, 
4.81; N, 7.86%. Found: C, 77.45; H, 4.75; N, 7.75%. 
(E)-6-(m-Tolyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5j). Colourless crystals, 
yield 68%, m.p. 150–151 °C. IR (KBr) cm−1 1706 (C=O), 1680 (C=N); 1H-NMR (CDCl3): δ (ppm) 7.89 (d, 
J = 7.6 Hz, 2H), 7.52–7.70 (m, 3H), 7.09–7.21 (m, 2H), 6.93 (td, J = 7.5, 1.2 Hz, 1H), 6.80 (d, J = 7.9 Hz, 
2H), 5.51 (d, J = 4.1 Hz, 1H), 5.21 (d, J = 17.2 Hz, 1H), 4.57 (d, J = 16.8 Hz, 1H), 4.12–4.30 (m, 1H), 3.48 
(s, 2H), 0.95–1.13 (m, 1H). 13C-NMR (CDCl3) δ 166.38, 149.79, 148.69, 143.84, 132.14, 131.85, 131.51, 
128.83, 128.70, 128.42, 126.07, 125.73, 125.39, 124.96, 124.64, 124.13, 123.88, 122.81, 121.14, 55.59, 45.80, 
41.91, 21.31. MS (ESI m/z) 353.3 [M]+. Anal. Calcd. For: C24H20N2O: C, 81.79; H, 5.72; N, 7.95%. Found: 
C, 81.54; H, 5.53; N, 7.68%. 
(E)-6-(o-Tolyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5k). Light yellow 
crystals, yield 40%, m.p. 155–156 °C. IR (KBr) cm−1 1687 (C=O), 1298 (C-O), 1623 (C=N). 1H-NMR 
(CDCl3): δ (ppm) 8.05 (d, J = 8.2 Hz, 2H), 7.77–7.88 (m, 2H), 7.73 (dd, J = 7.6, 1.7 Hz, 1H), 7.50–7.61 (m, 
1H), 7.40–7.50 (m, 2H), 7.36 (d, J = 8.2 Hz, 1H), 7.21–7.32 (m, 1H), 7.10 (td, J = 7.6, 1.4 Hz, 1H), 7.00 (dd, 
J = 7.7, 1.2 Hz, 1H), 5.27 (d, J = 14.4 Hz, 1H), 4.52 (d, J = 10.7 Hz, 1H), 3.68 (d, J = 14.4 Hz, 1H), 3.61 (dd, 
J = 13.7, 1.4 Hz, 1H), 2.43–2.54 (m, 3H), 2.26 (dd, J = 13.6, 10.8 Hz, 1H). 13C-NMR (CDCl3) δ 167.08, 
165.44, 148.78, 143.86, 141.81, 134.22, 131.66, 131.50, 129.72, 129.38, 128.67, 128.27, 127.63, 126.14, 
125.71, 124.85, 123.87, 122.84, 121.80, 121.17, 56.44, 41.92, 36.06, 21.43. MS (ESI m/z) 353.3. Anal. Calcd. 
For: C24H20N2O: C, 81.79; H, 5.72; N, 7.95%. Found: C, 81.50; H, 5.58; N, 7.90%. 
(E)-6-(3-Methoxyphenyl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5l). Light 
yellow crystals, yield 62%, m.p. 210–211 °C. IR (NKBr) cm−1 1692 (C=O), 1265 (C-O), 1616 (C=N). 1H-
NMR (CDCl3): δ (ppm) 7.80 (d, J = 7.6 Hz, 1H), 7.71–7.78 (m, 2H), 7.63–7.71 (m, 1H), 7.52–7.63 (m, 2H), 
7.38–7.52 (m, 3H), 7.22–7.34 (m, 1H), 7.06–7.17 (m, 1H), 7.01 (dd, J = 7.9, 1.4 Hz, 1H), 5.29 (d, J = 14.4 
Hz, 1H), 4.54 (d, J = 10.7 Hz, 1H), 3.92 (s, 3H), 3.69 (d, J = 14.4 Hz, 1H), 3.61 (dd, J = 13.7, 1.4 Hz, 1H), 
2.27 (dd, J = 13.6, 10.8 Hz, 1H). 13C-NMR (CDCl3) δ 167.06, 165.36, 160.20, 148.62, 143.81, 138.49, 132.51, 
131.70, 131.55, 129.91, 128.73, 128.70, 126.08, 125.01, 123.88, 121.82, 121.08, 119.90, 117.40, 112.80, 56.40, 
55.50, 41.92, 36.29. MS (ESI m/z) 369.3 [M]+. Anal. Calcd. For: C24H20N2O2: C, 78.24; H, 5.47; N, 7.60%. 
Found: C, 78.15; H, 5.45; N, 7.55%. 
(E)-6-(Thiophen-2-yl)-7,7a-dihydrobenzo[6,7][1,5]diazocino[2,1-a]isoindol-12(14H)-one (5m). Light yellow 
crystals, yield 32%, m.p. 279–280 °C. IR (KBr) cm−1 1694 (C=O), 1661 (C=N). 1H-NMR (CDCl3): δ (ppm) 
7.78–7.86 (m, 1H), 7.33–7.52 (m, 3H), 7.15–7.30 (m, 2H), 7.04–7.15 (m, 2H), 6.56–6.69 (m, 2H), 4.95–5.13 
(m, 2H), 4.36–4.54 (m, 1H), 3.67–3.78 (m, 1H), 3.21 (dd, J = 17.4, 8.0 Hz, 1H). 13C-NMR (CDCl3) δ 167.10, 
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160.69, 144.47, 143.90, 143.73, 132.62, 131.82, 131.66, 131.50, 128.90, 128.77, 128.50, 128.09, 126.80, 
125.34, 124.04, 121.90, 121.61, 56.95, 42.08, 37.31. MS (ESI m/z) 345.2 [M]+. Anal. Calcd. For: 
C21H16N2OS: C, 73.23; H, 4.68; N, 8.13%. Found: C, 73.05; H, 4.55; N, 8.05%. 
4. Conclusions 
In conclusion, we have developed a simple two-step synthetic route to the 
benzo[6,7][1,5]diazocino [2,1-a]isoindole fused ring system from readily available starting materials. 
A number of 3-(2-oxo-2-phenylethyl)isobenzofuran-1(3H)-ones 4a–4m were reacted in boiling 
toluene with 2-aminobenzylamine under para-toluenesulfonic acid catalysis to yield the fused 
diazocine derivatives 5a–5m in 27%–85% yields. The structure of the regioisomer formed has been 
confirmed unambiguously by rigorous multinuclear HMBC measurements. Biological evaluation of 
the synthesized compounds are currently under investigation and will be reported in future 
communications. 
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